Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2022-03-04 Capital/Financing Update
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Result of Fundraise
Capital/Financing Update Classification · 98% confidence The document is an RNS announcement (indicated by 'RNS Number : 7473D') dated March 4, 2022. The primary subject is the 'Successful Placing' and 'Fundraise' of new shares, raising gross proceeds of approximately £9.55 million. This involves the issuance of new shares and details related to capital structure changes and associated related party transactions (Harwood Capital, EKF participation). This clearly falls under the category of company fundraising and capital structure updates. The most specific code for this activity is 'CAP' (Capital/Financing Update). Although it is an RNS announcement, the content is substantive financial/capital news, not just a notice of publication, making CAP more appropriate than RNS or RPA.
2022-03-04 English
Close of Accelerated Bookbuild
Capital/Financing Update Classification · 95% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement. The content discusses the 'Close of Accelerated Bookbuild' and a 'Fundraise,' which are activities related to capital raising or financing. The document explicitly states that a 'further announcement will be made in due course confirming details of the Fundraise,' suggesting this is an update or initial announcement about a financing event, rather than the final detailed report itself. The presence of the RNS header strongly suggests a regulatory filing. Since the content is about the conclusion of a bookbuild related to a fundraise, the most appropriate category is 'Capital/Financing Update' (CAP). However, because this is a formal announcement disseminated via the Regulatory News Service (RNS) system, and it is an update on a transaction rather than a comprehensive report, it could also fit under the general 'Regulatory Filings' (RNS) category if CAP is too specific for an update notice. Given the explicit focus on the 'Fundraise' and 'Bookbuild,' CAP is highly relevant. Since it is a formal regulatory announcement, RNS is also plausible. Comparing CAP (Capital/Financing Update) and RNS (Regulatory Filings - fallback), the specific nature of the content (closing a bookbuild for a fundraise) points strongly to CAP. If the document were just a generic market update without specific financial transaction details, RNS would be better. I will classify it as CAP due to the specific subject matter, recognizing it is delivered via the RNS mechanism.
2022-03-04 English
Proposed Fundraise
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement filed via RNS (Regulatory News Service), indicated by the 'RNS Number' header and the use of 'National Storage Mechanism'. The core subject is the 'Proposed Fundraise to raise not less than £10.0 million' via a Placing and Subscription, which involves the non-pre-emptive issue of new ordinary shares. This activity directly relates to company fundraising and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the content is highly specific to a capital raise, making CAP more precise than the general fallback RNS.
2022-03-04 English
Successful completion of analytical validation
Environmental & Social Information Classification · 99% confidence The document begins with 'RNS Number : 6561B' and contains standard regulatory boilerplate language at the end, including references to RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). The content announces a specific operational milestone ('Successful completion of analytical validation for Clarava™ and Tuteva™') and provides context about product development and future commercialization. This structure—a brief, timely announcement of a specific corporate event or operational update disseminated via the RNS system—is characteristic of a general regulatory announcement that doesn't fit into the more specific categories like 10-K, ER, or DIV. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements.
2022-02-15 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document explicitly states it is an announcement regarding an 'Investor Presentation' where the CEO and CFO will provide a 'live progress and strategy update presentation'. This content directly aligns with the definition of an Investor Presentation (IP). Although it is distributed via RNS, the core subject matter is the presentation itself, not a general regulatory update or the announcement of a different report type. The document is short and serves to inform investors about an upcoming presentation event.
2022-01-14 English
Progress and strategy update
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 2523Y' and is dated '12 January 2022'. It provides a 'Progress and strategy update' for the year ended 31 December 2021, detailing product milestones (Clarava™, Tuteva™, Protega™), laboratory certifications (CLIA1), CPT code grants, and financial status ($10.3m cash balance). This content is characteristic of a corporate update released via a regulatory news service. The presence of the RNS header and the nature of the content (progress update, outlook, financial summary) strongly suggest it is a regulatory announcement. Since it is not a full Annual Report (10-K), a formal Earnings Release (ER), or a specific legal/governance document, and it is clearly distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements not covered by more specific codes like ER or 10-K.
2022-01-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.